Anna Sjögren
Chief Tech/Sci/R&D Officer bei EGETIS THERAPEUTICS AB
Profil
Anna Sjögren is currently the Director-Project & Clinical Development at Egetis Therapeutics AB.
Previously, she worked as the Director-Clinical Operations at OxThera AB from 2013 to 2017.
She received her undergraduate degrees from Karolinska Institutet and the University of Uppsala.
Aktive Positionen von Anna Sjögren
| Unternehmen | Position | Beginn |
|---|---|---|
| EGETIS THERAPEUTICS AB | Chief Tech/Sci/R&D Officer | - |
Ehemalige bekannte Positionen von Anna Sjögren
| Unternehmen | Position | Ende |
|---|---|---|
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Corporate Officer/Principal | 01.12.2017 |
Ausbildung von Anna Sjögren
| Karolinska Institutet | Undergraduate Degree |
| University of Uppsala | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| EGETIS THERAPEUTICS AB | Health Technology |
| Private Unternehmen | 1 |
|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
